Literature DB >> 31901077

Mitochondrial residence of the apoptosis inducer BAX is more important than BAX oligomerization in promoting membrane permeabilization.

Tomomi Kuwana1, Louise E King2, Katia Cosentino3, Julian Suess4, Ana J Garcia-Saez5, Andrew P Gilmore2, Donald D Newmeyer6.   

Abstract

Permeabilization of the mitochondrial outer membrane is a key step in the intrinsic apoptosis pathway, triggered by the release of mitochondrial intermembrane space proteins into the cytoplasm. The BCL-2-associated X apoptosis regulator (BAX) protein critically contributes to this process by forming pores in the mitochondrial outer membrane. However, the relative roles of the mitochondrial residence of BAX and its oligomerization in promoting membrane permeabilization are unclear. To this end, using both cell-free and cellular experimental systems, including membrane permeabilization, size-exclusion chromatography-based oligomer, and retrotranslocation assays, along with confocal microscopy analysis, here we studied two BAX C-terminal variants, T182I and G179P. Neither variant formed large oligomers when activated in liposomes. Nevertheless, the G179P variant could permeabilize liposome membranes, suggesting that large BAX oligomers are not essential for the permeabilization. However, when G179P was transduced into BAX/BCL2 agonist killer (BAK) double-knockout mouse embryonic fibroblasts, its location was solely cytoplasmic, and it then failed to mediate cell death. In contrast, T182I was inefficient in both liposome insertion and permeabilization. Yet, when transduced into cells, BAXT182I resided predominantly on mitochondria, because of its slow retrotranslocation and mediated apoptosis as efficiently as WT BAX. We conclude that BAX's mitochondrial residence in vivo, regulated by both targeting and retrotranslocation, is more significant for its pro-apoptotic activity than its ability to insert and to form higher-order oligomers in model membranes. We propose that this finding should be taken into account when developing drugs that modulate BAX activity.
© 2020 Kuwana et al.

Entities:  

Keywords:  Bax; anticancer drug; apoptosis; liposome; mitochondrial apoptosis; mitochondrial localization; mitochondrial outer membrane permeabilization (MOMP); molecular cell biology; protein oligomers; translocation

Mesh:

Substances:

Year:  2020        PMID: 31901077      PMCID: PMC7008371          DOI: 10.1074/jbc.RA119.011635

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  Structure of Bax: coregulation of dimer formation and intracellular localization.

Authors:  M Suzuki; R J Youle; N Tjandra
Journal:  Cell       Date:  2000-11-10       Impact factor: 41.582

2.  Bax transmembrane domain interacts with prosurvival Bcl-2 proteins in biological membranes.

Authors:  Vicente Andreu-Fernández; Mónica Sancho; Ainhoa Genovés; Estefanía Lucendo; Franziska Todt; Joachim Lauterwasser; Kathrin Funk; Günther Jahreis; Enrique Pérez-Payá; Ismael Mingarro; Frank Edlich; Mar Orzáez
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-27       Impact factor: 11.205

3.  The C-terminal helix of Bcl-x(L) mediates Bax retrotranslocation from the mitochondria.

Authors:  F Todt; Z Cakir; F Reichenbach; R J Youle; F Edlich
Journal:  Cell Death Differ       Date:  2012-10-19       Impact factor: 15.828

4.  VDAC2 inhibits BAK activation and mitochondrial apoptosis.

Authors:  Emily H Y Cheng; Tatiana V Sheiko; Jill K Fisher; William J Craigen; Stanley J Korsmeyer
Journal:  Science       Date:  2003-07-25       Impact factor: 47.728

5.  Examining the molecular mechanism of bcl-2 family proteins at membranes by fluorescence spectroscopy.

Authors:  Justin Kale; Xiaoke Chi; Brian Leber; David Andrews
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

6.  Bax assembles into large ring-like structures remodeling the mitochondrial outer membrane in apoptosis.

Authors:  Lena Große; Christian A Wurm; Christian Brüser; Daniel Neumann; Daniel C Jans; Stefan Jakobs
Journal:  EMBO J       Date:  2016-01-18       Impact factor: 11.598

Review 7.  The BCL-2 arbiters of apoptosis and their growing role as cancer targets.

Authors:  Jerry M Adams; Suzanne Cory
Journal:  Cell Death Differ       Date:  2017-11-03       Impact factor: 15.828

8.  BFL1 modulates apoptosis at the membrane level through a bifunctional and multimodal mechanism showing key differences with BCLXL.

Authors:  Hector Flores-Romero; Olatz Landeta; Begoña Ugarte-Uribe; Katia Cosentino; Miguel García-Porras; Ana J García-Sáez; Gorka Basañez
Journal:  Cell Death Differ       Date:  2018-12-18       Impact factor: 15.828

9.  Bax exists in a dynamic equilibrium between the cytosol and mitochondria to control apoptotic priming.

Authors:  Barbara Schellenberg; Pengbo Wang; James A Keeble; Ricardo Rodriguez-Enriquez; Scott Walker; Thomas W Owens; Fiona Foster; Jolanta Tanianis-Hughes; Keith Brennan; Charles H Streuli; Andrew P Gilmore
Journal:  Mol Cell       Date:  2013-01-31       Impact factor: 17.970

Review 10.  ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.

Authors:  Shundong Cang; Chaitanya Iragavarapu; John Savooji; Yongping Song; Delong Liu
Journal:  J Hematol Oncol       Date:  2015-11-20       Impact factor: 17.388

View more
  10 in total

1.  Lipids modulate the BH3-independent membrane targeting and activation of BAX and Bcl-xL.

Authors:  Victor Vasquez-Montes; Mykola V Rodnin; Alexander Kyrychenko; Alexey S Ladokhin
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-14       Impact factor: 11.205

Review 2.  Mitochondrial outer membrane permeabilization at the single molecule level.

Authors:  Shashank Dadsena; Andreas Jenner; Ana J García-Sáez
Journal:  Cell Mol Life Sci       Date:  2021-02-12       Impact factor: 9.261

Review 3.  The regulatory function of mixed lineage kinase 3 in tumor and host immunity.

Authors:  Sandeep Kumar; Sunil Kumar Singh; Basabi Rana; Ajay Rana
Journal:  Pharmacol Ther       Date:  2020-10-09       Impact factor: 13.400

4.  Revealing the Potential Application of EC-Synthetic Retinoid Analogues in Anticancer Therapy.

Authors:  Mohamed R Abdelaal; Sameh H Soror; Mohamed R Elnagar; Hesham Haffez
Journal:  Molecules       Date:  2021-01-19       Impact factor: 4.411

5.  BCL-2-family protein tBID can act as a BAX-like effector of apoptosis.

Authors:  Hector Flores-Romero; Lisa Hohorst; Malina John; Marie-Christine Albert; Louise E King; Laura Beckmann; Tamas Szabo; Vanessa Hertlein; Xu Luo; Andreas Villunger; Lukas P Frenzel; Hamid Kashkar; Ana J Garcia-Saez
Journal:  EMBO J       Date:  2021-12-21       Impact factor: 11.598

Review 6.  Bcl-2 Family Members and the Mitochondrial Import Machineries: The Roads to Death.

Authors:  Lisenn Lalier; François Vallette; Stéphen Manon
Journal:  Biomolecules       Date:  2022-01-19

7.  The interplay between BAX and BAK tunes apoptotic pore growth to control mitochondrial-DNA-mediated inflammation.

Authors:  Katia Cosentino; Vanessa Hertlein; Andreas Jenner; Timo Dellmann; Milos Gojkovic; Aida Peña-Blanco; Shashank Dadsena; Noel Wajngarten; John S H Danial; Jervis Vermal Thevathasan; Markus Mund; Jonas Ries; Ana J Garcia-Saez
Journal:  Mol Cell       Date:  2022-02-03       Impact factor: 17.970

8.  An explicitly designed paratope of amyloid-β prevents neuronal apoptosis in vitro and hippocampal damage in rat brain.

Authors:  Ashim Paul; Sourav Kumar; Sujan Kalita; Sourav Kalita; Dibakar Sarkar; Anirban Bhunia; Anupam Bandyopadhyay; Amal Chandra Mondal; Bhubaneswar Mandal
Journal:  Chem Sci       Date:  2020-12-22       Impact factor: 9.825

9.  Oxidative Stress Activated by Sorafenib Alters the Temozolomide Sensitivity of Human Glioma Cells Through Autophagy and JAK2/STAT3-AIF Axis.

Authors:  Jianwei Wei; Zhengfeng Wang; Weiwei Wang; Xiaoge Liu; Junhu Wan; Yongjie Yuan; Xueyuan Li; Liwei Ma; Xianzhi Liu
Journal:  Front Cell Dev Biol       Date:  2021-06-14

10.  High-resolution analysis of the conformational transition of pro-apoptotic Bak at the lipid membrane.

Authors:  Laura E Sperl; Florian Rührnößl; Anita Schiller; Martin Haslbeck; Franz Hagn
Journal:  EMBO J       Date:  2021-09-15       Impact factor: 11.598

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.